Mind Medicine(NASDAQ:MNMD) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET
Company Participants
Rob Barrow - CEO
Dan Karlin - Chief Medical Officer
Miri Halperin Wernli - Executive President
Conference Call Participants
Patrick Trucchio - H.C. Wainwright
Michael Okunewitch - Maxim
Elemer Piros - ROTH Capital
Sepehr Manochehry - Eight Capital
Tania Armstrong-Whitworth - Canaccord Genuity
Operator
Good morning and welcome to the Mind Medicine First Quarter 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only-mode. This call is being webcast live on the Investors and Media section of MindMed's website at mindmed.co and a recording will be available after the call.
For opening remarks, I would like to introduce Rob Barrow, CEO of MindMed. Please go ahead, sir.
Rob Barrow
Thank you, and good morning. I appreciate everyone joining us for our first quarter 2022 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of MindMed's website and our quarterly report on Form 10-Q for the year ended March 31, 2022 will be filed today with the Securities and Exchange Commission.
Joining me today is Dr. Daniel Karlin, our Chief Medical Officer; and Dr. Miri Halperin Wernli, our Executive President.
During today's call, we will be making certain forward-looking statements, including without limitation, statements about the potential, safety, efficacy and regulatory and clinical progress of our product candidate, financial projections and our future expectations, plans, partnerships and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including the most recent Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which are made as of today, May 16, 2022.
MindMed disclaims any obligation to update such statements even if management views change.Before we dive into our program and corporate update, I would like to reemphasize our ambition to transform the treatment of brain health disorders by delivering on the therapeutic potential of psychedelics and other novel targets.
We are applying our pharmaceutical expertise to develop innovative therapies with the aim of generating rapid and sustained improvement in patient outcomes, with applicability to anxiety, addiction and even autism. This is more important now than ever.The good news is that there has been a significant expansion in research to treat these conditions, and MindMed is leading the way in this effort.